KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer

KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma

(2017) Jonas Cicenas et al.   MEDICAL ONCOLOGY

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer

(2017) Hideyuki Hayashi et al.   PANCREAS

Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/mL

(2016) Jin-Feng Xiang et al.   Scientific Reports

Retraction Note to: Retraction: Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/mL

(2016) Jin-Feng Xiang et al.   Scientific Reports

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts

(2015) I Lohse et al.   BRITISH JOURNAL OF CANCER

Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer

(2015) Julia Carnevale et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia

(2015) Lika'a Fasih Y. Al-Kzayer et al.   PEDIATRIC BLOOD & CANCER

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

(2015) Talia Golan et al.   Oncotarget

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

(2014) Steffen Ormanns et al.   BMC CANCER

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer

(2013) L. Huang et al.   CARCINOGENESIS

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

(2013) Stefan Boeck et al.   JOURNAL OF GASTROENTEROLOGY

SMAD4 Genetic Alterations Predict a Worse Prognosis in Patients With Pancreatic Ductal Adenocarcinoma

(2012) Puneet Singh et al.   PANCREAS

The Predictive Role of p16 Deletion, p53 Deletion, and Polysomy 9 and 17 in Pancreatic Ductal Adenocarcinoma

(2012) Yanli Luo et al.   PATHOLOGY & ONCOLOGY RESEARCH

Prevalence ofBRCA1andBRCA2mutations in Ashkenazi Jewish families with breast and pancreatic cancer

(2011) Zsofia K. Stadler et al.   CANCER

Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy

(2011) Amir Sonnenblick et al.   CANCER BIOLOGY & THERAPY

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

(2011) S. T. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Elevated Transcript Levels From the MDM2 P1 Promoter and Low p53 Transcript Levels Are Associated With Poor Prognosis in Human Pancreatic Ductal Adenocarcinoma

(2010) Lukasz Filip Grochola et al.   PANCREAS

Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature

(2009) Edward James et al.   ANTI-CANCER DRUGS

SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer

(2009) A. Blackford et al.   CLINICAL CANCER RESEARCH

Polymorphisms of p16, p27, p73, and MDM2 Modulate Response and Survival of Pancreatic Cancer Patients Treated with Preoperative Chemoradiation

(2008) Jinyun Chen et al.   ANNALS OF SURGICAL ONCOLOGY